Keywords: Nycomed, Third quarter 2009 results, Pantoprazole, Daxas
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
Article | 13 November 2009
Privately-owned Swiss prescription and over-the-counter drugmaker Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing 0.9% (3.2% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
